
3 Oncology Medicines Firm, Fluorochemicals Producer and Hospital Software Provider Stocks With a Strong Future Roadmap: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions
Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions: ROE of 15.4% to 25.8% and FY22 to FY26 revenue CAGR of 21.0% to 42.2%. Prices as of 18 Nov 2026.
Updated: 19 Nov 2026 • 2:42 pm
Posted by:

Quick Answer
The three cancer drug, fluorine and health IT stocks to watch are Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Their return on equity ranges from 15.4% to 25.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 42.2%. Inventurus Knowledge Solutions leads on both return on equity at 25.8% and revenue growth at 42.2% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Cancer drug, fluorine and health IT stocks let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions cover a specialty drugs maker, a fluorine chemicals maker and a healthcare IT services company.
This list covers three cancer drug, fluorine and health IT stocks with complete current figures: Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Cancer Drug, Fluorine and Health IT Stocks?
Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets.
Cancer Drug, Fluorine and Health IT Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 820.6 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Navin Fluorine International | 10,278 | 41,847 | 53.0 | 35.1 | 16.7 | 0.32 |
| Inventurus Knowledge Solutions | 1,610.1 | 29,242 | 38.3 | 17.6 | 25.8 | 0.27 |
On valuation, Natco Pharma trades at a P/E below the industry P/E, while Navin Fluorine International and Inventurus Knowledge Solutions trade above it, which reflects the growth the market already expects. Readers comparing cancer drug, fluorine and health IT stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cancer drug, fluorine and health IT stocks can use the coming numbers to test whether growth is holding.
Why Do Cancer Drug, Fluorine and Health IT Stocks Have a Strong Roadmap in India?
Cancer drug, fluorine and health IT stocks have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies.
- Specialty drugs. Patients need advanced treatments.
- Fluorine chemicals. Cooling and battery makers need fluorine inputs.
- Healthcare IT. Providers digitise their operations.
Why Natco Pharma Features Among These Cancer Drug, Fluorine and Health IT Stocks
Among the cancer drug, fluorine and health IT stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Navin Fluorine International Features Among These Cancer Drug, Fluorine and Health IT Stocks
Among the oncology generics, refrigerant inputs and hospital software shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.
In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%.
Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1.
Roadmap: Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.
What to watch: Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.
Why Inventurus Knowledge Solutions Features Among These Cancer Drug, Fluorine and Health IT Stocks
Among the three companies on this list, Inventurus Knowledge Solutions, known as IKS, is a Mumbai-based healthcare technology and services company that supports healthcare providers and payors in the United States with analytics, clinical coding and technology platforms.
The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P/E of 38.3, above the industry P/E of 17.6.
Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore.
Roadmap: The company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.
What to watch: Follow client additions, platform adoption and healthcare policy changes in the United States.
Natco Pharma vs Navin Fluorine International vs Inventurus Knowledge Solutions on Key Financials
The table below sets the three cancer drug, fluorine and health IT stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Navin Fluorine International | 1,493 | 3,379 | 22.7% | 664 | 19.6% |
| Inventurus Knowledge Solutions | 784 | 3,211 | 42.2% | 722 | 22.5% |
Inventurus Knowledge Solutions posts the highest return on equity in this group at 25.8%. Natco Pharma has the largest FY26 revenue at Rs 4,376 crore, and Inventurus Knowledge Solutions shows the fastest revenue growth with a 42.2% compound annual rate. A useful habit with cancer drug, fluorine and health IT stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Cancer Drug, Fluorine and Health IT Stocks
Every theme carries risks that deserve a check before any decision. For these cancer drug, fluorine and health IT stocks, the main points are: Long-term oncology generics, refrigerant inputs and hospital software shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Client spending. Technology budgets can vary with global conditions.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter cancer drug, fluorine and health IT stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Cancer Drug, Fluorine and Health IT Stocks
Cancer drug, fluorine and health IT stocks reward investors who follow demand trends, order books and margins together. Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions each have a clear plan to grow. Based on the 18 November 2026 close, Natco Pharma trades at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these cancer drug, fluorine and health IT stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track cancer drug, fluorine and health IT stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are cancer drug, fluorine and health IT stocks?
Ans. Cancer drug, fluorine and health IT stocks are listed companies that make specialty medicines for cancer and other serious conditions, make fluorine based chemicals for cooling, batteries and drugs, and provide technology and data services to healthcare providers. Their earnings depend on medicine demand, specialty chemical orders and healthcare technology budgets. This list looks at three of them, Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which cancer drug, fluorine and health IT stocks are covered in this list?
Ans. This list covers Natco Pharma, Navin Fluorine International and Inventurus Knowledge Solutions. Based on the 18 November 2026 close, Natco Pharma traded at Rs 820.6, Navin Fluorine International at Rs 10,278 and Inventurus Knowledge Solutions at Rs 1,610.1. Their return on equity ranges from 15.4% to 25.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 42.2%.
Why do cancer drug, fluorine and health IT stocks have a strong future roadmap in India?
Ans. Cancer drug, fluorine and health IT stocks have a strong roadmap in India because rising demand for advanced medicines, rising demand for fluorine chemicals and wider healthcare digitisation keep widening the market for these companies. The main drivers are as follows. Specialty drugs. Patients need advanced treatments. Fluorine chemicals. Cooling and battery makers need fluorine inputs. Healthcare IT. Providers digitise their operations. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Navin Fluorine International performed financially?
Ans. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.
How has Inventurus Knowledge Solutions performed financially?
Ans. Revenue rose from Rs 784 crore in FY22 to Rs 3,211 crore in FY26, a compound annual growth rate of 42.2%. Net profit grew from Rs 233 crore in FY22 to Rs 722 crore in FY26, which works out to a compound annual growth rate of 32.7%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 899 crore, while net profit rose 27.8% to Rs 194 crore. The company has a return on equity of 25.8%, a debt to equity ratio of 0.27 and a market capitalisation of Rs 29,242 crore. The stock trades at a P/E of 38.3, above the industry P/E of 17.6. Looking ahead, the company is widening its technology-led services for risk adjustment, care coordination and revenue cycle work. Long-term relationships with large healthcare organisations give it recurring demand.
What risks should investors check before buying cancer drug, fluorine and health IT stocks?
Ans. Investors should check a few risks before buying cancer drug, fluorine and health IT stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of cancer drug, fluorine and health IT stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Maritime Stocks Compared: Adani Ports vs JSW Infrastructure vs Great Eastern Shipping vs SCI vs Cochin Shipyard on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Under Rs 2,500 Stocks Compared: Hindustan Unilever vs Adani Ports vs Mazagon Dock vs Phoenix Mills vs Waaree Energies on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Under Rs 250 Stocks Compared: Tata Steel vs Adani Power vs ONGC vs Sonata Software vs Vedanta on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Under Rs 150 Stocks Compared: IRB Infrastructure vs Suzlon vs SJVN vs NHPC vs Indian Oil on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Maritime Stocks Compared: Adani Ports vs JSW Infrastructure vs Great Eastern Shipping vs SCI vs Cochin Shipyard on Price, Valuation, Q2 FY27 Results and Risks
Top Under Rs 2,500 Stocks Compared: Hindustan Unilever vs Adani Ports vs Mazagon Dock vs Phoenix Mills vs Waaree Energies on Price, Valuation, Q2 FY27 Results and Risks
Top Under Rs 250 Stocks Compared: Tata Steel vs Adani Power vs ONGC vs Sonata Software vs Vedanta on Price, Valuation, Q2 FY27 Results and Risks
Top Under Rs 150 Stocks Compared: IRB Infrastructure vs Suzlon vs SJVN vs NHPC vs Indian Oil on Price, Valuation, Q2 FY27 Results and Risks
Top Small-Cap Low-PB Stocks Compared: PNC Infratech vs HG Infra vs RCF vs Finolex Industries vs Chambal Fertilisers on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





